Tianjin (CNS) – A new AIDS vaccine has completed its first phase of clinical testing and the second phase is set to begin, thanks to Shao Yiming and his research group.
"The long-term and wide use of the smallpox vaccine enhanced its safety and reliability to be chosen as the medium to foster AIDS vaccine", said Shao, an AIDS expert and the director of the AIDS research center at Nankai University, adding that they employed genetic technology to produce the first generation of AIDS vaccine produced from live samples, and at a lower cost than the inactive variety.
The clinical test proved the viability of the first generation of the AIDS vaccine to be used in inoculations. Results from the second phase of vaccine testing are expected to be in by the end of this year or the first half of next year, said Shao.
